<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03269422</url>
  </required_header>
  <id_info>
    <org_study_id>17-407</org_study_id>
    <nct_id>NCT03269422</nct_id>
  </id_info>
  <brief_title>Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)</brief_title>
  <official_title>A Phase I Feasibility Study of Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR Image-Guided, Intensity-Modulated Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to find out the feasibility and effects of ultra-hypofractionated
      radiotherapy to the prostate and dominant lesion as definitive treatment for intermediate
      risk prostrate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2017</start_date>
  <completion_date type="Anticipated">August 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related toxicity of ultra-hypofractionated radiotherapy will be assessed according to NCI CTCAE v3.0 gastrointestinal or genitourinary toxicity</measure>
    <time_frame>36 months</time_frame>
    <description>Assess toxicity of ultra-hypofractionated radiotherapy to the prostate and dominant lesion as definitive treatment for intermediate risk prostate cancer. Severe Toxicity will be assessed and defined as Grade 3 or higher NCI CTCAE v3.0 gastrointestinal or genitourinary toxicity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>MR Image Guided, Intensity-Modulated Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in this study will undergo MR-based, image-guided, intensity-modulated radiotherapy using similar equipment, techniques, and treatment-planning procedures as currently practiced at MSKCC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>MR-based image-guided, intensity-modulated radiotherapy</intervention_name>
    <description>Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.</description>
    <arm_group_label>MR Image Guided, Intensity-Modulated Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermediate risk prostate cancer patients will be eligible for this study. Risk
             groups will be assigned as per NCCN guidelines. Intermediate risk patients will be
             defined as:

               -  PSA 10-20 ng/ml or

               -  Gleason score = 7 or

               -  Clinical stage T2b/T2c

          -  Additionally, patients will be required to meet the following criteria:

               -  Age ≥ 18

               -  KPS ≥ 80

               -  Prostate size ≤ 60cc

               -  Presence of a prostatic lesion with maximum dimension of &gt;/= 0.5cm and no more
                  than two additional disease foci, each with a maximum dimension less than that of
                  the dominant lesion.

               -  International Prostrate Symptom Score ≤ 15

               -  Subjects must fill out the standard MRI screening form and satisfy all MRI
                  screening criteria

        Exclusion Criteria:

          -  Prior androgen deprivation therapy for prostate cancer

          -  Evidence of metastatic disease on bone scan or MRI/CT

          -  MRI ineligibility due to the presence of a cardiac pacemaker, defibrillator or other
             implanted metallic or electronic device which is considered MR unsafe, severe
             claustrophobia or inability to lie flat for the duration of the study, etc.

          -  Metallic hip implant, metallic implant or device in the pelvis that might distort the
             local magnetic field and compromise quality of MP-MRI.

          -  Lateral pelvic separation greater than 50 cm and/or anterior-posterior separation
             greater than 35 cm which are incompatible with MRCAT reconstruction

          -  Contra-indications to receiving gadolinium contrast

          -  KPS &lt; 80

          -  Pelvic MRI or CT (MRI preferred) evidence of radiographic T3, T4 or N1 disease.

          -  Prior history of transurethral resection of the prostate

          -  Prior history of chronic prostatitis

          -  Prior history of urethral stricture

          -  Prior history of pelvic irradiation

          -  History of inflammatory bowel disease

          -  Unable to give informed consent

          -  Unable to complete quality of life questionnaires

          -  Abnormal complete blood count. Any of the following

               -  Platelet count less than 75,000/ml

               -  Hb level less than 10 gm/dl

               -  WBC less than 3.5/ml

          -  Abnormal renal function tests (creatinine &gt; 1.5)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Zelefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Zelefsky, MD</last_name>
    <phone>212-639-6802</phone>
    <email>zelefskm@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margie Hunt, MS</last_name>
    <phone>212-639-6646</phone>
    <email>huntm@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center 1275 York Avenue</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
    <investigator>
      <last_name>Michael Zelefsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Zelefsky, MD</last_name>
      <phone>212-639-6802</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>August 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>17-407</keyword>
  <keyword>Intermediate Risk Prostate Cancer</keyword>
  <keyword>DIL</keyword>
  <keyword>Dominant Intra-Prostatic Lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

